IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1026-1050 out of 1235.

<< < 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 > >>

Public Release: 21-May-2014
JAMA Surgery
Study examines prophylactic double mastectomy following breast cancer diagnosis
Many women diagnosed with cancer in one breast consider, and eventually undergo, a contralateral prophylactic mastectomy to remove both breasts, although few of them have a clinically significant risk of developing cancer in both breasts.

Contact: Nicole Fawcett
The JAMA Network Journals

Public Release: 21-May-2014
ASCO 50th Annual Meeting
EORTC to present cancer research results at ASCO 2014
The EORTC will present nine abstracts at the ASCO 2014 Annual Meeting which will be held May 30-June 3, 2014, in Chicago, Ill. Four abstracts will be presented in Oral Abstract Sessions, one in a Poster Highlights Session, and another four in General Poster Sessions.

Contact: John Bean
European Organisation for Research and Treatment of Cancer

Public Release: 21-May-2014
JAMA Surgery
Most women who have double mastectomy don't need it, U-M study finds
About 70 percent of women who have both breasts removed following a breast cancer diagnosis do so despite a very low risk of facing cancer in the healthy breast, new research from the University of Michigan Comprehensive Cancer Center finds.
NIH/National Cancer Institute

Contact: Nicole Fawcett
University of Michigan Health System

Public Release: 21-May-2014
Journal of Translational Medicine
Cancer avatars for personalized medicine
Researchers at University of California, San Diego School of Medicine and Moores Cancer Center have used computer simulations of cancer cells -- cancer avatars -- to identify drugs most likely to kill cancer cells isolated from patients' brain tumors.
National Brain Tumor Society, Barbara and Joseph Ajello Trust Fund, Tuttleman Family Foundation

Contact: Scott LaFee
University of California - San Diego

Public Release: 21-May-2014
Molecule acts as umpire to make tough life-or-death calls
Researchers have demonstrated that an enzyme required for animal survival after birth functions like an umpire, making the tough calls required for a balanced response to signals that determine if cells live or die. St. Jude Children's Research Hospital scientists led the study, which was published online and appears in the May 22 edition of the scientific journal Cell.
National Institutes of Health, ALSAC

Contact: Carrie Strehlau
St. Jude Children's Research Hospital

Public Release: 21-May-2014
Molecular Cancer Therapeutics
Finnish researchers discovered a new anticancer compound
A team of research scientists from VTT Technical Research Centre of Finland, the University of Turku and the University of Eastern Finland has discovered a previously unknown Cent-1 molecule that kills cancer cells.

Contact: Marko Kallio
VTT Technical Research Centre of Finland

Public Release: 21-May-2014
Molecular Cancer Research
Molecule linked to aggressive pancreatic cancer offers potential clinical advances
Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.
NIH/National Cancer Institute, Mayo Clinic SPORE in Pancreatic Cancer

Contact: Kevin Punsky
Mayo Clinic

Public Release: 21-May-2014
Cell Reports
TSRI scientists catch misguided DNA-repair proteins in the act
Scientists led by a group of researchers at The Scripps Research Institute in La Jolla, CA, have discovered some of the key proteins involved in one type of DNA repair gone awry.
Pew Scholars, National Institutes of Health, Novartis Advanced Discovery Institute, Italian Ministry of Health, FIRC

Contact: Madeline McCurry Schmidt
Scripps Research Institute

Public Release: 21-May-2014
Journal of Urology
Study shows image fusion-guided biopsy improves accuracy of prostate cancer diagnosis
The detection rate is twice as high using MRI and ultrasound fusion-guided biopsy.

Contact: Betty Olt
North Shore-Long Island Jewish (LIJ) Health System

Public Release: 21-May-2014
Drug-target database lets researchers match old drugs to new uses
A study recently published in the journal Bioinformatics describes a new database and pattern-matching algorithm that allows researchers to evaluate rational drugs and drug combinations, and also recommends a new drug combination to treat drug-resistant non-small cell lung cancer.
National Institutes of Health

Contact: Garth Sundem
University of Colorado Denver

Public Release: 21-May-2014
Nature Chemical Biology
Team validates potentially powerful new way to treat HER2-positive breast cancer
A CSHL-led research team reports that it has found a means of inhibiting a protein called PTP1B, whose expression is upregulated in HER2-positive breast cancer. They show that PTP1B plays a critical role in the development of tumors in which HER2 signaling is aberrant. Therefore, PTP1B may be a therapeutic target via which to treat the disease.
National Institutes of Health, Cold Spring Harbor Laboratory Cancer Center, American Diabetes Association

Contact: Peter Tarr
Cold Spring Harbor Laboratory

Public Release: 21-May-2014
International Journal of Cancer
The interruption of biological rhythms during chemotherapy worsen its side effects
Patients receiving chemical treatment for cancer often suffer fatigue and body weight loss, two of the most worrying effects of this therapy linked to the alteration of their circadian rhythms.

Contact: Press Office
FECYT - Spanish Foundation for Science and Technology

Public Release: 20-May-2014
Genomic tumor testing to match lung cancer patients with targeted drugs transforms care
New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.
NIH/National Cancer Institute

Contact: Melissa Morgenweck
Memorial Sloan-Kettering Cancer Center

Public Release: 20-May-2014
American Society for Microbiology 114th General Meeting
More than two-thirds of healthy Americans are infected with human papilloma viruses
In what is believed to be the largest and most detailed genetic analysis of its kind, researchers at NYU Langone Medical Center and elsewhere have concluded that 69 percent of healthy American adults are infected with one or more of 109 strains of human papillomavirus.

Contact: David March
NYU Langone Medical Center / New York University School of Medicine

Public Release: 20-May-2014
Research identifies genetic alterations in lung cancers that help select treatment
Multiplexed testing of lung cancer tumors identified genetic alterations that were helpful in selecting targeted treatments. Patients that received matched therapy for lung cancer lived longer than patients who did not receive directed therapy, although randomized clinical trials are required to determine if this treatment strategy improves survival, according to a study in the May 21 issue of JAMA.

Contact: Melissa Morgenweck
The JAMA Network Journals

Public Release: 20-May-2014
American Urological Association Annual Meeting
Prolaris test predicts mortality risk in prostate cancer biopsy study
Data presented at AUA 2014 show the Prolaris test accurately predicted mortality risk from prostate cancer within 10 years in patients diagnosed with needle biopsy. The use of this test could improve treatment for patients at all risk levels based on each man's personal risk of disease progression. Prolaris has been proven to predict prostate cancer-specific disease progression in 11 clinical trials with more than 6,000 patients.

Contact: Ronald Rogers
Myriad Genetics, Inc.

Public Release: 20-May-2014
Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
Research explains action of drug that may slow aging and related disease
A proven approach to slow the aging process is dietary restriction, but new research helps explain the action of a drug that appears to mimic that process -- rapamycin. The advance moves science closer to a compound that might slow aging and reduce age-related disease.
National Institutes of Health

Contact: Viviana Perez
Oregon State University

Public Release: 20-May-2014
Molecular Cancer Therapeutics
Pine bark substance could be potent melanoma drug
A substance that comes from pine bark is a potential source for a new treatment of melanoma, according to Penn State College of Medicine researchers.
National Institutes of Health, Foreman Foundation for Melanoma Research, H.G. Barsumian, M.D. Memorial Fund

Contact: Matt Solovey
Penn State

Public Release: 20-May-2014
Nicotine and Tobacco Research
Students swayed by 'relaxing, fun' image of hookah smoking ignore health harms
Educational campaigns meant to dissuade college students from initiating hookah tobacco smoking may be more successful if they combat positive perceptions of hookah use as attractive and romantic, rather than focusing solely on the harmful components of hookah tobacco smoke, a new University of Pittsburgh School of Medicine study found.
NIH/National Cancer Institute, Steven Manners Memorial Fund

Contact: Allison Hydzik
University of Pittsburgh Schools of the Health Sciences

Public Release: 20-May-2014
Study shows how streptococcal bacteria can be used to fight colon cancer
Researchers at Western University have shown how the bacteria primarily responsible for causing strep throat can be used to fight colon cancer. By engineering a streptococcal bacterial toxin to attach itself to tumor cells, they are forcing the immune system to recognize and attack the cancer. The study found the engineered bacterial toxin could significantly reduce the size of human colon cancer tumors in mice, with a drastic reduction in the instances of metastasis.
Canadian Institutes of Health Research

Contact: Kathy Wallis
519-661-2111 x81136
University of Western Ontario

Public Release: 19-May-2014
Annals of Internal Medicine
Study calls for revisiting cardiac screening guidelines for survivors of childhood cancer
One of the first studies to analyze the effectiveness of screening survivors of childhood cancer for early signs of impending congestive heart failure finds improved health outcomes but suggests that less frequent screening than currently recommended may yield similar clinical benefit. The researchers, in a study published in the Annals of Internal Medicine, utilized a simulation-based model to estimate the long-term benefits associated with routine screening.
NIH/National Cancer Institute

Contact: Irene Sege
Dana-Farber Cancer Institute

Public Release: 19-May-2014
Journal of Urology
Low risk prostate cancer not always low risk
Selection of men for active surveillance should be based not on the widely used conventional biopsy, but with a new, image-guided targeted prostate biopsy.
NIH/National Cancer Institute

Contact: Kim Irwin
University of California - Los Angeles Health Sciences

Public Release: 19-May-2014
Angewandte Chemie
Scripps Research Institute chemists discover structure of cancer drug candidate
Chemists at The Scripps Research Institute have determined the correct structure of a highly promising anticancer compound approved by the US Food and Drug Administration for clinical trials in cancer patients. The new report, published this week by the international chemistry journal Angewandte Chemie, focuses on a compound called TIC10.
Skaggs Institute for Chemical Biology, Scripps Research Institute

Contact: Mika Ono
Scripps Research Institute

Public Release: 19-May-2014
Journal of Clinical Oncology
A call to arms in cancer research
The rapid growth in the Hispanic population in the US is not matched by growth in Hispanics participating in cancer clinical trials -- not even close. Given the health disparities experienced by this population it is crucial that cancer researchers include more Hispanics in their trials, and there are steps they can take to do so, in an analysis from the Cancer Therapy & Research Center at the UT Health Science Center San Antonio.
NIH/National Cancer Institute

Contact: Elizabeth Allen
University of Texas Health Science Center at San Antonio

Public Release: 19-May-2014
American Urological Association Annual Meeting
Robot-assisted prostate cancer surgery as safe but more expensive as open surgery in older men
Minimally invasive robot-assisted surgery, which has become the main choice for surgically removing cancerous prostate glands during recent years, is as safe as open surgery for Medicare patients over age 65. Those are the primary findings of a newly published nationwide patient survey that included participation by researchers at Henry Ford Hospital, a pioneer of robot-assisted radical prostatectomy.

Contact: Dwight Angell
Henry Ford Health System

Showing releases 1026-1050 out of 1235.

<< < 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 > >>

  Search News Releases